TRU: AI-driven cervical cancer screening sales up 27% YOY, led by China and LMIC expansion

About this update from Truscreen Group Ltd.

AI-enabled cervical cancer screening device sales grew 27% YOY, driven by strong adoption in China and expansion into LMICs. Recurring revenue from single-use sensors and strategic partnerships support growth, with clinical trials confirming high sensitivity and specificity.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Truscreen Group Ltd.